Proactive Investors - Run By Investors For Investors

ANGLE agreement could open up whole new area of cancer diagnostics

The deal is with the Barts Cancer Institute and focuses on the breakthrough made by its researchers in determining the role of megakaryocytes
patient with doctor
The technology may provide a weapon in the fight against prostate cancer

ANGLE PLC (LON:AGL, OTCQX:ANPCY) has signed an option agreement over an advance that may open a “whole new area of cancer diagnostics”.

The deal is with the Barts Cancer Institute and focuses on the breakthrough made by its researchers in determining the role of megakaryocytes.

Found in the blood they correlate closely with survival rates for patients with prostate cancer.

Their presence and abundance could allow doctors to more precisely tailor treatments so they are more effective.

Partsortix holds key to harvesting 

ANGLE’s Parsortix liquid biopsy is the only device currently able to harvest megakaryocytes.

Queen Mary University of London, of which the Barts Cancer Institute is a part, has filed two worldwide patent applications related to its work.

The AIM-listed med-tech firm has agreed to cover the costs of that process in return for a two-year option over patents covering any medical therapeutic, diagnostic, or prophylactic application. 

WATCH: ANGLE inks agreement with world-leading molecular testing provider

READ: Broker targeting near-tripling in ANGLE's share price as Parsortix development strides forward

The company’s chief executive, Andrew Newland, said: "This deal further strengthens ANGLE's intellectual property position in the fast-emerging liquid biopsy market.

“Use of the Parsortix system is driving new discoveries by key opinion leaders and customers and ANGLE is the obvious partner to drive their commercialisation so we expect to see other similar developments over time continually strengthening the Company's position in the market."

ANGLE shares were 2.5% higher in morning trade at 34.5p, but small-cap broker finnCap believes the stock has much further to go.

“We make no changes to our forecasts and retain our 100p price target, which is based on a DCF [discounted cash flow] analysis,” said analyst Mark Brewer in a short note to clients.

“But [we] point to the significant long-term value potential additional value that could be generated by any clinical applications arising from the combination of Parsortix and the downstream analysis of captured megakaryocytes.”

---adds broker comment and share price---

View full AGL profile View Profile

ANGLE plc Timeline

Related Articles

boy leaning against chain link fence
September 14 2017
We take a look back at the progress made by Summit in the five years since we first spoke to chief executive Glyn Edwards
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use